Eralp Yesim, Ates Utku
Maslak Acıbadem Hospital, Acıbadem University, Istanbul 34398, Turkey.
Biotech4life Tissue and Cell R&D Center, Stembio Cell and Tissue Technologies, Inc., Istanbul 34398, Turkey.
Vaccines (Basel). 2023 Sep 29;11(10):1545. doi: 10.3390/vaccines11101545.
Malignant neoplasms arising from the gastrointestinal (GI) tract are among the most common types of cancer with high mortality rates. Despite advances in treatment in a small subgroup harboring targetable mutations, the outcome remains poor, accounting for one in three cancer-related deaths observed globally. As a promising therapeutic option in various tumor types, immunotherapy with immune checkpoint inhibitors has also been evaluated in GI cancer, albeit with limited efficacy except for a small subgroup expressing microsatellite instability. In the quest for more effective treatment options, energetic efforts have been placed to evaluate the role of several immunotherapy approaches comprising of cancer vaccines, adoptive cell therapies and immune checkpoint inhibitors. In this review, we report our experience with a personalized dendritic cell cancer vaccine and cytokine-induced killer cell therapy in three patients with GI cancers and summarize current clinical data on combined immunotherapy strategies.
起源于胃肠道（GI）的恶性肿瘤是最常见的癌症类型之一，死亡率很高。尽管在一小部分具有可靶向突变的亚组中治疗取得了进展，但结果仍然很差，占全球观察到的与癌症相关死亡的三分之一。作为各种肿瘤类型中一种有前景的治疗选择，免疫检查点抑制剂免疫疗法也已在胃肠道癌症中进行了评估，尽管除了一小部分表达微卫星不稳定性的亚组外，疗效有限。为了寻求更有效的治疗选择，人们已经做出了积极的努力来评估几种免疫疗法的作用，包括癌症疫苗、过继性细胞疗法和免疫检查点抑制剂。在这篇综述中，我们报告了我们对三名胃肠道癌症患者使用个性化树突状细胞癌症疫苗和细胞因子诱导的杀伤细胞疗法的经验，并总结了联合免疫疗法策略的当前临床数据。
